Review
Version 1
Preserved in Portico This version is not peer-reviewed
Proposing Bromo-Epi-Androsterone for Neurologic Long-COVID
Version 1
: Received: 30 June 2024 / Approved: 1 July 2024 / Online: 1 July 2024 (17:58:01 CEST)
How to cite: Dow, C. T. Proposing Bromo-Epi-Androsterone for Neurologic Long-COVID. Preprints 2024, 2024070115. https://doi.org/10.20944/preprints202407.0115.v1 Dow, C. T. Proposing Bromo-Epi-Androsterone for Neurologic Long-COVID. Preprints 2024, 2024070115. https://doi.org/10.20944/preprints202407.0115.v1
Abstract
The neurologic effects of long-COVID are a therapeutic challenge. This article discusses the immunologic manifestations of long-COVID and proposes a non-androgenic, synthetic analog of dehydroepiandrosterone (DHEA), bromo-epi-androsterone (BEA), as a candidate for clinical trials for this exigent collection of neurologic conditions. Moreover, because there is an association between long-COVID and Alzheimer’s disease, the evaluation of BEA in long-COVID may serve as a proxy for its effect on neuroinflammatory biomarkers of Alzheimer’s disease that are shared with long-COVID.
Keywords
SARS-CoV-2; Long-COVID; brain fog, immune dysregulation, dehydroepiandrosterone (DHEA); bromo-epi-androsterone (BEA); biomarkers; neuroinflammation; Alzheimer’s.
Subject
Medicine and Pharmacology, Epidemiology and Infectious Diseases
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (0)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment